OncLive TV

John M. Pagel, MD, PhD, discusses the utility of rituximab with etoposide, doxorubicin, cyclophosphamide, vincristine, and prednisone in double- and triple-hit lymphoma.

Alan P. Z. Skarbnik, MD, discusses future combination therapies with tazemetostat in follicular lymphoma.

Daniel P. Petrylak, MD, discusses the pivotal trials that have led to the regulatory approvals of the PARP inhibitors olaparib and rucaparib in patients with metastatic castration-resistant prostate cancer and DNA repair mutations.

Alan P. Z. Skarbnik, MD, highlights the approval of tazemetostat in relapsed/refractory follicular lymphoma.

Raajit K. Rampal, MD, PhD, discusses challenges with targeting high-risk mutations in patients with myelofibrosis.

Lori A. Leslie, MD, discusses developments in CAR T-cell therapy in diffuse large B-cell lymphoma and mantle cell lymphoma.

John M. Burke, MD, discusses risk stratifications strategies in follicular lymphoma. 

Arun Azad, PhD, discusses the results of the post-hoc analyses of the phase 3 ARCHES trial in men with metastatic hormone-sensitive prostate cancer.

Daniel P. Petrylak, MD, discusses the role of prostate-specific antigen screening in prostate cancer.

Connie L. Batlevi, MD, PhD, discusses emerging therapies in follicular lymphoma.

Alan P. Z. Skarbnik, discusses ongoing research with PI3​K inhibitors in follicular lymphoma. 

John M. Burke, MD, discusses treatment options in relapsed/refractory follicular lymphoma.

Maha Hussain, MD, FACP, FASCO, discusses the importance of genomic profiling in metastatic castration-resistant prostate cancer.

Paul L. Nguyen, MD, discusses standard and investigational treatment options in high-risk prostate cancer.

Benjamin P. Levy, MD, discusses the disease-free survival benefit with adjuvant osimertinib in the phase 3 ADAURA trial.

Natalie I. U. Vokes, MD, discusses investigative biomarkers of response to checkpoint inhibitors in the field of oncology.

Arun Azad, PhD, discusses unmet needs for men with metastatic hormone-sensitive prostate cancer.

Andrew B. Nixon, PhD, ​MBA, discusses the role of microsatellite instability in cancer.

Petros Grivas, MD, PhD, discusses findings from the subgroup analyses of JAVELIN Bladder 100 in advanced urothelial cancer.

Aditya Bardia, MD, MPH, discusses the need to develop additional therapies for patients with metastatic triple-negative breast cancer.

Shuo Ma, MD, PhD, discusses the utility of BTK inhibitors in relapsed/refractory chronic lymphocytic leukemia.

Erlene Seymour, MD, discusses the progression-free survival benefit with acalabrutinib with or without obinutuzumab in chronic lymphocytic leukemia.

Mattia Garutti, MD, discusses the potential shift to neoadjuvant therapy in melanoma.

Raajit K. Rampal, MD, PhD, discusses the evolving understanding of genetic alterations in myeloproliferative neoplasms.

Maha Hussain, MD, FACP, FASCO, discusses the clinical impact of the phase 3 PROfound trial in metastatic castration-resistant prostate cancer.

Lori A. Leslie, MD, lymphoma attending, John Theurer Cancer Center, discusses sequencing strategies with zanubrutinib in mantle cell lymphoma.

Erika P. Hamilton, MD, discusses ​the final overall survival results from the ​randomized, phase 2 nextMONARCH trial in patients with hormone receptor–positive​, HER2-negative metastatic breast cancer.

Ruben A. Mesa, MD, discusses emerging therapies in myelofibrosis.

Kami J. Maddocks, MD, discusses ongoing sequencing challenges in diffuse large B-cell lymphoma.

John M. Burke, MD, discusses the potential benefits of time-limited therapy with BTK inhibitors in B-cell malignancies.